Accessed - 640 times.

Imaduddin Quazi1*, Sastry VG2, Sastry VH1
1Department of Pharmaceutical Sciences, MESCO College of Pharmacy, Hyderabad-500006, India.
2Department of Pharmaceutical Sciences. College of Pharmacy. Andhra University, Visakhapatnam, 530003, AP, India.

Volume 2, Issue 1, Jan-April 2014, Page 64-71.

Article history
Received: 05 January 2014
Revised: 18 January 2014
Accepted: 25 February 2014
Early view: 20 April 2014

*Author for correspondence

Parkinson’s disease

Epilepsy, multiple sclerosis, parkinson’s disease etc. are the neurological disorders which inflict great pain and suffering on patients and their families. A report of a population-based neuroepidemiological study of 102,557 individuals in urban and rural of Bangalore in Southern India showed that the neurological disorders were detected in 3,206 persons resulting in crude and age-adjusted frequency rates of 3,126 and 3,355 per 100,000 population, respectively. The prevalence rate was 2,653,3,932, and 5,012 per 100,000 population, respectively among children, middle-aged (31-40 years old) and elderly persons. It has been postulated that the neurological disorders were twice as frequent in rural areas as in urban. To avert and treat neurological disorders, biopharmaceutical research companies are recently developing 444 medicines. Indoles, aromatic heterocyclic organic compound became the precursor to many pharmacological agents. Different biological evaluation of the new compounds as acetylcholinesterase inhibitors has been performed. Most of the compounds have been claimed to have potent acetylcholinesterase inhibitor activity.